3BNC117-LS First-in-Human Phase 1 Study

NCT03254277 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

DRUG: 3BNC117-LS
DRUG: Placebo

Sponsor

Rockefeller University